This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy and Cookie Notice.

Skip to main content

Latest News

Teva Announces Virtual 2020 Annual Meeting of Shareholders

Teva Announces Virtual 2020 Annual Meeting of Shareholders

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremane...

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab

Teva presenterà nuove analisi su AJOVY® (fremanezumab) e i dati più recenti su COPAXONE® (glatiramer...

Teva presenterà nuove analisi su AJOVY® (fremanezumab) e i dati più recenti su COPAXONE® (glatiramer acet

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate inj...

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskine...

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia i

Teva Reports First Quarter 2020 Financial Results

Teva Reports First Quarter 2020 Financial Results

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumat...

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid A

New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Inclu...

New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included i

Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm) Injection

Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm) Injection

Teva Drives Positive Impact in Response to COVID-19 Pandemic

Teva Drives Positive Impact in Response to COVID-19 Pandemic

Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, ...

Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, 2020

Teva Statement on Donation of COVID-19 Related Treatments

Teva Statement on Donation of COVID-19 Related Treatments

Teva Update Regarding COVID-19

Teva Update Regarding COVID-19

Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationw...

Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide

Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injectio...

Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection

Avis favorable de l'Institut national pour l'excellence clinique (NICE) pour le premier traitement a...

Avis favorable de l'Institut national pour l'excellence clinique (NICE) pour le premier traitement anti-P

Positive Empfehlung des NICE für die erste, gegen das CGRP gerichtete Migränetherapie: AJOVY®▼ (Frem...

Positive Empfehlung des NICE für die erste, gegen das CGRP gerichtete Migränetherapie: AJOVY®▼ (Fremanezu

Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®▼ (fremanezumab)

Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®▼ (fremanezumab)

Teva Announces FDA Approval of ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder

Teva Announces FDA Approval of ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder

Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome ...

Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did N

Global HOPE, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children...

Global HOPE, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children with Cancer in Africa

New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion

New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan

Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan

Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector

Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector

Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Gui...

Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance

Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Note...

Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes

Teva Announces $1.5 Billion Debt Tender Offers

Teva Announces $1.5 Billion Debt Tender Offers

Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosi...

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar

Teva Announces Appointment of New Chief Financial Officer

Teva Announces Appointment of New Chief Financial Officer

Teva Reports Third Quarter 2019 Financial Results

Teva Reports Third Quarter 2019 Financial Results

Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7,

Teva to Present New Analyses of Fremanezumab and Country-Specific Burden of Migraine at 24th World C...

Teva to Present New Analyses of Fremanezumab and Country-Specific Burden of Migraine at 24th World Congress of Neurology

Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation ...

Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

Teva Announces Leadership Change in its Global Operations Group

Teva Announces Leadership Change in its Global Operations Group

Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Adv...

Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to...

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Trea

Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days...

Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Vers

Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-...

Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

Teva Announces CFO Leadership Transition

Teva Announces CFO Leadership Transition

Teva Reports Second Quarter 2019 Financial Results

Teva Reports Second Quarter 2019 Financial Results

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 ...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg)

Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus ...

Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection at the American Headache Society’s ...

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection at the American Headache Society’s 61st

Teva to Host Conference Call to Discuss Second Quarter 2019 Financial Results at 8 a.m. ET on August...

Teva to Host Conference Call to Discuss Second Quarter 2019 Financial Results at 8 a.m. ET on August 7, 2

Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase ...

Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb

Teva Announces Launch of 1% Sodium Hyaluronate in the United States

Teva Announces Launch of 1% Sodium Hyaluronate in the United States